The latest innovation
and company news

EpiDisease receives an investment of 535,000€ for the development of diagnostic tests with epigenetic markers. Arquimea and the Fundación Botín invest in diagnostic tests based on epigenetics which will accelerate the market launch of this technology and undertake trials in Spanish hospitals.

Starting this week, travellers from Madrid-Barajas, Malaga, and Seville airports will have a COVID 19 test service in their departure terminals. This service will permit taking PCR Tests and Rapid Antigen Tests to travellers and crews, who need to prove they underwent these tests during their journey.